<DOC>
	<DOC>NCT00157950</DOC>
	<brief_summary>This is an immunogenicity and safety study of Gardasil (V501) in females 9 to 23 years of age in Korea.</brief_summary>
	<brief_title>Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED)</brief_title>
	<detailed_description />
	<mesh_term>Papillomavirus Infections</mesh_term>
	<criteria>Girls ages 9 to 15 years (must not yet have had coitarche) Healthy females ages 16 to 23 years (individuals with a lifetime history of 0 to 3 male or female sexual partners) All Subjects: History of known prior vaccination with an HPV vaccine. Women Ages 16 to 23 Only: Individuals with any prior history of genital warts or treatment for genital warts. Individuals with &gt; 3 lifetime male or female sexual partners.</criteria>
	<gender>Female</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>23 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Human Papilloma Virus</keyword>
</DOC>